Compare Johnson & Johnson (JNJ) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Total International Stock Index Fund ETF — how do they compare? Johnson & Johnson trades at $259.8 (market cap $626.09B), while Vanguard Total International Stock Index Fund ETF trades at $87.61. The key difference: Johnson & Johnson pays a 2.06% dividend while Vanguard Total International Stock Index Fund ETF pays none, and Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Johnson & Johnson nearer its low. Which is the better fit depends on your goals.
| JNJ | VXUS | |
|---|---|---|
Market Cap | $626.09B | — |
Volume | 6,156,228 | — |
Sector | Health | Sector/Thematic |
52-Week High | $267.24 | $87.21 |
52-Week Low | $172.78 | $70.87 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
VXUS, the Vanguard Total International Stock ETF, trades at $87.72, up 1.02% on the day, with a bullish technical signal driven by strong moving average alignment. Recent news highlights its role in global diversification, with a 27.82% total return over the past year noted by Seeking Alpha on August 8, 2026. The ETF offers exposure to over 8,700 non-U.S. stocks, attracting institutional interest, though RSI levels suggest potential near-term overbought conditions.
The outlook for VXUS is supported by its valuation discount to U.S. equities and broad diversification benefits, but risks include global economic sensitivity and inflationary pressures. Analyst sentiment is mixed, with some advocating buys for long-term portfolios while others caution on growth-inflation dynamics. Institutional holdings have increased, reflecting confidence in international market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
